Cytek Biosciences’ Northern Lights platform approved for clinical use in China

Clinical flow cytometry laboratories based in China can now go beyond 24 colors – easily and affordably. Cytek Biosciences Inc., a leading provider of flow cytometry instrumentation, has received approval from the China National Medical Products Administration (NMPA) for its Cytek® Northern Lights flow cytometer for clinical diagnostic use in hospitals, laboratories and clinics across China. This achievement comes on the heels of Cytek’s DxP Athena systems being cleared by the NMPA, and places the company on a path to offering a complete spectral flow cytometry solution to the Chinese market – from instruments to reagents.

Cytek Biosciences’ Northern Lights platform approved for clinical use in China
The China National Medical Products Administration (NMPA) has cleared Cytek Biosciences’ Northern Lights flow cytometer for clinical diagnostic use in hospitals, laboratories and clinics across China. (Credit: Cytek Biosciences)

At Cytek, we are fueling a movement to extend the benefits of flow cytometry from the few to the many.

A key part of this process is continuing to extend and accelerate our reach and capabilities. Achieving NMPA clearance is an important milestone – and a rigorous process. Our success speaks to our commitment to excellence and quality – from conception through manufacturing.”

Dr. Wenbin Jiang, CEO of Cytek Biosciences

Cytek Northern Lights offers a value-added package with capabilities that go beyond flow cytometry systems with a much higher price tag. Upgradeable and available in configurations from one laser (nine colors) to three lasers (24+ colors), Cytek’s Northern Lights series offers high sensitivity and reagent flexibility. With several configurations available, Cytek Northern Lights sits in a sweet spot for scientists that have budgeted for a one to three laser system, but desire the ability to run panels of higher complexity. Until now, such panels would only be achievable using a conventional flow cytometer’s most expensive configuration.

On a mission to make massively multiparametric flow cytometry accessible to a larger number of researchers, Cytek anticipates NMPA approval for its complete system application solution soon.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cytek Biosciences. (2019, September 12). Cytek Biosciences’ Northern Lights platform approved for clinical use in China. News-Medical. Retrieved on September 19, 2019 from https://www.news-medical.net/news/20190912/Cytek-Biosciencese28099-Northern-Lights-Platform-Approved-for-Clinical-Use-in-China.aspx.

  • MLA

    Cytek Biosciences. "Cytek Biosciences’ Northern Lights platform approved for clinical use in China". News-Medical. 19 September 2019. <https://www.news-medical.net/news/20190912/Cytek-Biosciencese28099-Northern-Lights-Platform-Approved-for-Clinical-Use-in-China.aspx>.

  • Chicago

    Cytek Biosciences. "Cytek Biosciences’ Northern Lights platform approved for clinical use in China". News-Medical. https://www.news-medical.net/news/20190912/Cytek-Biosciencese28099-Northern-Lights-Platform-Approved-for-Clinical-Use-in-China.aspx. (accessed September 19, 2019).

  • Harvard

    Cytek Biosciences. 2019. Cytek Biosciences’ Northern Lights platform approved for clinical use in China. News-Medical, viewed 19 September 2019, https://www.news-medical.net/news/20190912/Cytek-Biosciencese28099-Northern-Lights-Platform-Approved-for-Clinical-Use-in-China.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Cytek Biosciences introduces new Northern Lights series of advanced flow cytometry systems